Sopharma AD Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Ognian Donev
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 24.2yrs |
| CEO ownership | 8.8% |
| Management average tenure | no data |
| Board average tenure | 9.9yrs |
Recent management updates
Recent updates
Sopharma AD's (BUL:SFA) Problems Go Beyond Weak Profit
Sep 07
Here's Why Sopharma AD (BUL:SFA) Can Manage Its Debt Responsibly
Jun 02Sopharma AD (BUL:SFA) Has A Somewhat Strained Balance Sheet
Apr 09Here's Why We Think Sopharma AD (BUL:3JR) Is Well Worth Watching
Feb 20How Many Sopharma AD (BUL:3JR) Shares Do Institutions Own?
Feb 05Should You Rely On Sopharma AD's (BUL:3JR) Earnings Growth?
Jan 22Sopharma AD (BUL:3JR) Has A Somewhat Strained Balance Sheet
Jan 06
Sopharma AD (BUL:3JR) Share Prices Have Dropped 25% In The Last Three Years
Dec 22Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Dec 07Are Investors Undervaluing Sopharma AD (BUL:3JR) By 29%?
Nov 19Should Sopharma AD (BUL:3JR) Be Part Of Your Dividend Portfolio?
Jul 07CEO
Ognian Donev (67 yo)
24.2yrs
Tenure
лв723,162
Compensation
Mr. Ognian Ivanov Donev, D.Sc. (Econ.), Ph D., serves as the Executive Chairman at Sopharma AD and Sopharma Trading AD and also served as Chief Executive Officer since September 2021 until November 2021. M...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 24.2yrs | лв723.16k | 8.76% BGN 83.9m | |
| Deputy Chairman | no data | лв173.75k | 0.000090% BGN 862.2 | |
| Director | 6.3yrs | лв252.59k | 0.0012% BGN 11.7k | |
| Independent Director | 13.5yrs | лв120.00k | 0.27% BGN 2.6m | |
| Director | 3.5yrs | no data | 0.021% BGN 197.6k |
9.9yrs
Average Tenure
61yo
Average Age
Experienced Board: SFA's board of directors are considered experienced (9.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 18:59 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sopharma AD is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mihail Dimitrov | First Financial Brokerage House |
| Bram Buring | Wood & Company |